Advanced donor origin melanoma in a renal transplant recipient: Immunotherapy, cure, and retransplantation

Transplantation

Volumn 66, Issue 5, 1998, Pages 655-661

  Suranyi, M G ^a,b   Hogan, Patrick G ^a   Falkk, Michael C ^a   Axelsen, Roy A ^a   Rigby, Rüssel ^a   Hawley, Carmel ^a   Petrie, James ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b LIVERPOOL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; TUMOR VACCINE;

ADULT; ARTICLE; CANCER IMMUNIZATION; CASE REPORT; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY TRANSPLANTATION; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON ALFA-2A; KIDNEY TRANSPLANTATION; MALE; MELANOMA; MIDDLE AGED; TISSUE DONORS; TRANSPLANTATION IMMUNOLOGY;

EID: 0032530961     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199809150-00020     Document Type: Article

References (26)

1. Harvey L, Fox M. Transferral of malignancy as a complication of organ transplantation: an insuperable problem? J Clin Pathol 1981; 34: 116.
2. Sanfilippo F. The transmission of disease to allograft recipients via donor organs. Curr Opin Immunol 1989; 1: 1225.
3. Martin DC, Rubini M, Rosen VJ. Cadaveric renal Homotransplantation with inadvertent transplantation of cancer. JAMA 1965; 192: 82.
4. McPhaul JJ, McIntosh DA. Tissue transplantation still vexes. N Engl J Med 1965; 272: 105.
5. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996; 61: 274.
6. Jeremy D, Farnsworth RH, Robertson MR, et al. Transplantation of malignant melanoma with cadaver kidney. Transplantation 1972; 13: 619.
7. Peters MS, Stuard ID. Metastatic malignant melanoma transplanted via a renal homograft: a case report. Cancer 1978; 41: 2426.
8. Fairman RM, Grossman RA, Barker CF, Perloff LJ. Inadvertent transplantation of a melanoma. Transplantation 1980; 30: 328.
9. Younis FM, Fernando ON, Sweny P, Baillod R, Moorhead J. Malignant melanoma in patient with renal transplant. Lancet 1980; 2(8204):1141.
10. Wilson LJ, Horvat RT, Tilzer L, Meis AM, Montag L, Huntrakoon M. Identification of donor melanoma in a renal transplant recipient. Diagn Mol Pathol 1992; 1: 266.
11. Elder GJ, Hersey P, Branely P. Remission of transplanted melanoma: clinical course and tumour cell characterisation. Clin Transplant 1997; 11: 565.
12. Bishop GA, Hall BM, Suranyi MG, Tiller DJ, Horvath JS, Duggin GG. Expression of HLA antigens on renal tubular cells in culture. I. MLC supernatant and gamma interferon increase both class I and class II HLA antigens. Transplantation 1986; 42: 671.
13. Brossart P, Keilholz U, Scheibenbogen U, Mohler T, Willhauck M, Hunstein W. Detection of residual tumor cells in patients with malignant melanoma responding to immunotherapy. J Immunother 1994; 15: 38.
14. Penn I. Malignancy in transplanted organs [Editorial]. Transpl Int 1993; 6: 1.
15. Matter B, Zukowski CF, Killen DA, Ginn E. Transplanted carcinoma in an immunosuppressed patient. Transplantation 1970; 9: 71.
16. Wilson RN, Hager EB, Hampers CL, Corson JM, Merrill JP, Murray JE. Immunologic rejection of human cancer transplanted with a renal allograft. N Engl J Med 1968; 278: 479.
17. Perdrizet GA, Ross SR, Stauss HJ, Singh S, Koeppen H, Schreiber H. Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen. J Exp Med 1990; 171: 1205.
18. Kramer P, Bijnen AB, Ten Kate FWJ, Jeekel J. Recombinant leukocyte interferon A induces steroid resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1984; 1: 989.
19. Magnone M, Holley JL, Shapiro R, et al. Interferon-alpha induced acute renal allograft rejection. Transplantation 1995; 59: 1068.
20. Chakrabarti D, Huang X, Beck J, et al. Control of islet intercellular adhesion molecule-1 expression by interferon alpha and hypoxia. Diabetes 1996; 45: 1336.
21. Tsukada N, Aoka S, Maruyama S, Kishi K, Takahashi M, Aizawa Y. The heterogenous expression of CD80, CD86 and other adhesion molecules on leukemia and lymphoma cells and their induction by interferon. J Exp Clin Cancer Res 1997; 16: 171.
22. Suranyi MG, Bishop GA, Waugh J, Hall BM. Target susceptibility in cell-mediated lympholysis assays correlates with major histocompatibility complex surface antigen expression. Transplant Proc 1987; 19: 2869.
23. Fidler IJ, Heicappell R, Saiki I, Grutter MG, Horisberger MA, Nuesch J. Direct antiproliferative effects of recombinant human interferon alpha B/D hybrids on human tumor cell lines. Cancer Res 1987; 47: 2020.
24. Kirkwood JM, Ernstoff MS. Role of interferons in the therapy of melanoma. J Invest Dermatol 1990; 95:(6S): 180S.
25. Herberman RB, Ortaldo JR, Mantovani A, Hobbs DS, Kung H, Pestka S. Effects of human recombinant interferon on cytotoxic activity of natural killer cells and monocytes. Cell Immunol 1982; 67: 160.
26. Hersey P. Melanoma vaccines: current status and future prospects. Drugs 1994; 47: 373.